WO1998022130A1 - Local use of il-1ra in corneal transplant rejection or disorders of the eye - Google Patents
Local use of il-1ra in corneal transplant rejection or disorders of the eye Download PDFInfo
- Publication number
- WO1998022130A1 WO1998022130A1 PCT/US1997/021393 US9721393W WO9822130A1 WO 1998022130 A1 WO1998022130 A1 WO 1998022130A1 US 9721393 W US9721393 W US 9721393W WO 9822130 A1 WO9822130 A1 WO 9822130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic composition
- interleukin
- corneal
- treatment
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the prophylaxis and treatment of corneal transplant rejection and other immune and inflammatory disorders of the eye and more particularly to a topical treatment therefor.
- Corneal transplantation has emerged as the most common and successful form of solid tissue transplantation with over 40,000 cases performed in the United States alone (1) .
- the 2 -year survival rate is over 90% (2) .
- the extraordinary success of penetrating keratoplasty can be attributed to various features of the normal cornea and anterior segment that in the aggregate account for their "immune-privileged" state (3) including: (a) the avascularity of the stroma, (b) the absence of corneal lymphatics, (c) the rarity of indigenous professional antigen-presenting Langerhans cells (LC) or macrophages in the normal graft bed, (d) a unique spectrum of locally produced immunomodulatory cytokines that suppress immunogenic inflammation and complement activation (to which the cornea itself contributes) , and (e) expression of Fas ligand by these ocular tissues that can directly suppress immunogenic inflammation (4) .
- corticosteroids and their use in the prophylaxis and treatment of corneal transplant rejections has represented the most significant contribution to the prolongation of corneal transplant survival over the last several decades (11,12) .
- corticosteroids or alternative general immunosuppressants, is associated with significant complications such as infection, cataracts, glaucoma and corneal thinning
- Interleukin-1 is a potent proinflammatory cytokine that has a wide range of activities including the critical mediation of the acute-phase response, chemotaxis and activation of inflammatory and antigen-presenting cells, upregulation of adhesion molecules/ costimulatory factors on cells, and stimulation of neovascularization (17,18,19,20) .
- IL-1 has been implicated as an important cytokine in host immunologic reactions to a variety of non-ocular allografts (21,22,23).
- IL-1 activity has been correlated with corneal neovascularization (24) , endotoxin-mediated uveitis (25) , corneal collagenase and metalloprotease expression (26,27), corneal injury in vitamin-A deficiency (28) , and herpetic stromal keratitis (29) .
- Endotoxin-mediated uveitis (25)
- corneal collagenase and metalloprotease expression 26,27
- corneal injury in vitamin-A deficiency 8
- herpetic stromal keratitis 219
- IL-1 mediated Langerhans cell migration can play a critical role in host allosensitization in the setting of corneal transplantation (17,30). For all these reasons, IL-1 is an attractive target for therapeutic intervention in immunogenic inflammatory diseases.
- Interleukin-1 receptor antagonist is a naturally occurring IL-1 isoform with high-affinity binding to both IL-1 receptor subtypes. IL-lra functions as an active IL-1 inhibitor, having no agonist activity (31,32) . There is a 77% homology between the predominant human and murine isoforms of IL-lra, and systemic administration of recombinant human IL-lra has been shown to have a profound downregulatory effect on the acute phase cytokine cascade in both man and mouse (33,34) .
- IL-lra administration has a significant positive effect in promoting corneal allograft survival, i.e., in increasing survival rates, of both normal- and high-risk transplant recipients.
- both normal- and high-risk IL-lra treated graft sites had significantly less inflammation and Langerhans cell infiltration compared to untreated controls. Therefore, the invention is directed to a method for treating allografts and preventing allograft rejection, or for generally treating an immune or inflammatory response of the eye.
- the method of the invention includes direct, local application of a therapeutic composition to an affected area of a patient.
- the therapeutic composition useful in the method of the invention comprises a therapeutically effective amount of an interleukin-1 antagonist in association with a pharmaceutically acceptable carrier vehicle for local application.
- the therapeutic composition can be packaged as an article of manufacture of the invention that includes a label indicating the use of the composition in the method of the invention.
- the interleukin- 1 antagonist is an interleukin-1 receptor antagonist and, most preferably, the naturally occurring (or recombinant) human IL-1 isoform IL-lra. Alternatively, other interleukin- 1 antagonists may be utilized for the same effect.
- the carrier vehicle in the composition of the invention is preferably a viscous formulation, and most preferably, sodium hyaluronate for application to the corneal surface, to promote a longer residence time for the therapeutic agent at the affected site of the patient.
- sodium hyaluronate (or any other appropriate hyaluronate salt) can be used as a pharmaceutical carrier vehicle for the delivery of other therapeutic agents to the ocular surface of a patient.
- the method of the invention is used to prolong transplant survival in corneal allograft recipients.
- the method of the invention would also be useful for therapeutic intervention in immunogenic inflammatory diseases of the cornea and ocular surface, such as keratoconjunctivitis sicca and other dry eye states including Sj ⁇ gren's syndrome, allergic conjunctivitis and other atopic conditions of the ocular surface, corneal neovascularization, and immune or infectious keratitis states.
- the method of the invention upon local injection or irrigation, would be useful for suppressing diseases such as uveitis and post-surgical inflammation in intraocular compartments (e.g. , anterior chamber or vitreous cavity) .
- Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof and from the claims.
- Fig. 1 shows a conceptual relationship among corneal neovascularization, IL-lra treatment, and graft outcome based on degree of preoperative risk
- Fig. 2 shows Kaplan-Meier survival curves for normal -risk and high-risk corneal allograft recipients
- Figs. 3A and 3B show association between corneal allograft survival and neovascularization score in normal - risk recipients based on IL-lra treatment; and Fig. 4A and 4B show association between corneal allograft survival and neovascularization score in high-risk recipients based on IL-lra treatment.
- corticosteroids The currently available pharmaceutic armamentarium for corneal transplant survival is primarily composed of corticosteroids. Their introduction into ophthalmology is arguably the single most significant factor in the last four decades' advances in corneal transplant surgery (13) . Nevertheless, beyond their well-known serious complications, corticosteroids show widely variable efficacy in preventing ultimate immunogenic graft failure, and this is particularly the case in high-risk keratoplasty (1,7) .
- IL-lra treatment was determined to be associated with a blunted postkeratoplasty neovascularization response.
- Laboratory results show that IL-lra can significantly blunt the early, but not late, phase corneal neovascularization development m response to standard angiogenic stimuli, suggesting that there are non-IL-1 mediated factors that can overshadow IL-1 suppression m corneal angiogenesis .
- IL-lra The failure of IL-lra to lead to significant neovascularization regression m the high-risk beds, as opposed to its capacity for angiostas s m the normal-risk beds as demonstrated here, is apparently due to the dominance of non-IL-1 driven angiogenic factors m the former. However, IL-lra appears to play an important role, possibly m combination with other agent (s) m suppressing the neovascular response.
- corneal neovascularization causes sufficient perturbation of the ocular microenvironment to lead to a loss of "immune privilege" as measured by the ability to m ⁇ uce anterior chamber-associated immune deviation (ACAID) (35) .
- ACAID m ⁇ uce anterior chamber-associated immune deviation
- m contrast to the expectation that the efficacy with which IL-lra could blunt rejection m the high-risk corneas would be paralleled by an equal degree of suppression m corneal neovascularization
- treatment with IL-lra promotes allograft survival m recipients regardless of their neovascularization status. This effect could mirror what has been described previously m neovascularized corneas where therapeutic measures that have been shown to restore immune privilege/ACAID are associated with highly variable degrees of angiostasis (35) .
- IL-lra treatment 20 in the neovascularized cornea 18, the effect of IL-lra treatment 20 on corneal transplantation 16 appears to be independent of the degree of corneal neovascularization, which remains at the significant (+++NV) level 22. Specifically, IL-lra treatment of high-risk beds (with antecedent neovascularization) does not appear to significantly suppress neovascularization; however, this same treatment leads to significant prolongation of graft survival compared to untreated controls .
- IL-1 has been shown to be a critical regulator of LC migration m the cornea (17) , and the activity of epidermal LC is known to be at least partially controlled by IL-1 (30,49).
- IL-1 (30,49).
- the demonstrated constitutive expression by normal corneal cells of IL-lra (50) likely plays an important immune regulatory role m the avascular/non-traumatized cornea by keeping the microenvironment in an inhospitable site for sensitization.
- Topical preparations of the therapeutic agent were applied to the recipient mice three times daily for the 56 days (8 weeks) duration of the study.
- the study medication was composed of 20 mg/ml of human recombinant IL-lra in 0.2% sodium hyaluronate in PBS (supplied by Amgen, Boulder, CO) .
- Placebo-treated animals received the vehicle 0.2% sodium hyaluronate only. Graft success or failure was established based on opacity scores, as detailed in Materials and Methods below.
- Corneal transplant rejection rates stratified by IL-la therapy and degree of risk.
- Corneal Neovascularization In addition to graft survival/opacification criteria detailed in Materials and Methods, transplants were also followed biomicroscopically for the degree of corneal neovascularization. All high-risk beds had been specially prepared for two weeks to develop two or more quadrants of stromal neovascularization as described previously (36) , and all normal-risk corneal beds were avascular.
- the corneas were also examined to see if treatment with IL-lra had an appreciable effect on this parameter, and an angiostatic effect with IL-lra treatment m the normal -risk, but not high-risk, transplants was observed.
- Figs. 3A and 3B among the normal-risk grafts, 38% of the untreated corneas (Fig. 3A) had a neovascularization score of >3 at 4 weeks compared to none of the IL-lra treated cases (Fig. 3B) . Respective rates at 8 weeks were 31% for untreated controls and 18% for treated cases.
- Figs. 4A and 4B no significant association of angiostatic effect with IL-lra treatment was apparent m high-risk eyes that had been induced to have corneal neovascularization two weeks previously.
- the proportions of corneas with a neovascularization score of ⁇ 3 at 4 and 8 weeks follow-up was very comparable between untreated controls (Fig. 4A) (91% at both time points) and treated cases (Fig. 4B) (100% and 86% at respective time points) .
- LC Langerhans Cell Population.
- BALB/c corneas and allografts were excised at the completion of the follow-up period to assay their LC populations with fluorescence microscopy, as described m Materials and Methods .
- the decreased corneal inflammation in the IL-lra-treated allografts was reflected by a generally lower opacity score (irrespective of final rejection status) m the IL-lra-treated transplants.
- opacity score irrespective of final rejection status
- mice Materials and Methods Mice and anesthesia. Six to ten-week old BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice were purchased (Taconic, New York) or obtained from the Schepens Eye Research Institute animal colony. All animals were treated according to the Association for Research m Vision and Ophthalmology Statement for the Use of Animals m Ophthalmic and Vision
- Corneal transplantation All 55 transplants involved combined MHC- and minor alloantigen disparate corneas that were grafted from C57BL/6 donors into BALB/c eyes as follows. On day 0, m each case, the central 2 -mm of the donor cornea was marked with a microcurrette and the donor button excised by Vannas scissors and placed m phosphate-buffered saline
- the recipient graft bed was prepared by excising the central 2 -mm of the cornea.
- the donor button was then secured m place with 8 interrupted 11-0 nylon sutures
- Intrastromal sutures induce robust neovascularization growth into the normally avascular corneal stroma from the limbus that can be appreciated as early as three days following suture placement (35) , and untreated allografts into these high-risk beds are rejected swiftly (36).
- Two parallel protocols were devised to study normal- and high-risk corneal transplantation. In the former case, animals were left unmanipulated until the day of surgery. High-risk beds were developed as described previously (36) . Briefly, three interrupted 11-0 sutures were placed in the central cornea of one eye of a normal BALB/c mouse on day -14 under aseptic microsurgical technique using an operating microscope. The neovascularized beds then served as high-risk graft beds for orthotopic corneal transplants on day 0 as described above (neovascularization-inducing sutures were removed at the time of transplantation) . Neovascularization was graded between
- grafts with an opacity score of 2+ or greater at any time point after two weeks were considered to have a rejection reaction (RR) , regardless of the opacity score at eight weeks (37) .
- LC Langerhans cell
- the LC were assessed by an immunofluorescence assay performed on whole corneal epithelial mounts as previously described (38) . Briefly, each eye was enucleated and the anterior segment dissected under the operating microscope. The cornea was placed in 20mM ethylenediaminetetraacetic acid (EDTA) buffer and incubated for 30 minutes at 37°C, followed by removal of the epithelium in toto and washed in PBS at room temperature . The cornea was then fixed with 95% ethanol prior to washing and incubation with 1:20 diluted primary anti-murine Ia d antibody for 45 minutes at 37°C.
- EDTA ethylenediaminetetraacetic acid
- the tissue was then washed in PBS and incubated with a FITC-labeled goat anti-mouse secondary antibody for 30 minutes at 37°C. Negative controls either bypassed this step or were incubated with antibody specific for an unrelated MHC epitope. Sections were then mounted on slides and examined under the fluorescent microscope with a square ocular grid where LC were enumerated. Corneal specimens that were not processed for LC enumeration were fixed, sectioned, and stained with hematoxylin-eosin for light microscopic evaluation. Statistical techniques. The proportional rates of rejected allografts in the IL-lra and vehicle-only treated groups were compared using two methods.
- the Mantel - Haenszel summary chi-square statistic was obtained, stratified by (adjusted for) degree of preoperative risk (i.e., normal vs. vascularized stromal bed) to compare the proportion of rejected transplants in the two groups.
- Second, Kaplan-Meier survival curves were constructed in order to compare the probability of graft survival over the follow-up period, both overall and separately for normal- and high-risk eyes, in the IL-lra treated and untreated controls. This method accounted for the variability in the time-to- graft rejection in addition to the variation in follow-up time (4 mice in the normal -risk group had follow-up terminated prior to the end of the 8-week period) . Comparison of Langerhans cell population means among IL-lra treated eyes and untreated controls was made by the Student's t-test .
- IL-lra is a very promising agent for use in corneal transplantation, both because of its efficacy as demonstrated in these experimental results and its putative value over existing therapy, which has well-known side-effects and complications.
- the very significant dampening of the inflammatory response observed suggests that treatment with IL-lra and other antagonists of IL-1 and its receptors can be applied to a wide variety of ocular immune and inflammatory disorders.
- IL-1 antagonism e.g., via use of IL-lra, can suppress immunogenic inflammation, as demonstrated in the corneal transplant model herein, in both virgin and previously inflamed/neovascularized eyes.
- the topical administration of IL-lra can include non-transplant therapeutic uses such as treatment of allergic and hypersensitivity disorders of the ocular surface, burns, infections, dry eye disorders, and chronic inflammatory states that may lead to neovascularization and/or scarring or fibrosis of the cornea and ocular surface.
- non-transplant therapeutic uses such as treatment of allergic and hypersensitivity disorders of the ocular surface, burns, infections, dry eye disorders, and chronic inflammatory states that may lead to neovascularization and/or scarring or fibrosis of the cornea and ocular surface.
- other vehicles e.g., cyclodextrms may be used to increase drug deliver to the surface epithelium.
- IL-lra is not limited to topical administration to the cornea and ocular surface.
- Intraocular administration e.g., by intraocular injection into the anterior chamber or irrigation at the time of surgery, is appropriate for treatment (or prophylaxis of recurrence) of intraocular inflammatory disorders such as autoimmune or infectious uveitis, post-traumatic or post-surgical inflammation, or ldiopathic uveitides.
- Sustained release formulations e.g., with use of biodegradable or non- degradable biocompatible polymers, or simple irrigation of these agent (s) at the time of surgery, can be used for intraocular delivery of IL-lra to subjects.
- mterleukm-1 antagonists that might be useful m the methods of the invention, as described earlier, can be tested for effectiveness using one of the assays described herein (e.g., measuring the extent of corneal inflammation, neovascularization, graft survival or Langerhans cell migration) and the results compared to those obtained with IL-lra.
- IL-lra used m the experiments described herein was relatively high m order to determine the maximum positive effect of treatment. However, IL-lra appears to be able to exert its suppressive effect over a wide dose range (56) .
- Optimal dosage and appropriate modes of administration for each of the conditions delineated above can be determined by conventional protocols. For example, m the case of corneal transplantation, other doses ranging between 20ng/ml
- 2mg/ml will additionally be tested and the endpomts described above (e.g., effect on corneal inflammation, neovascularization, graft longevity or Langerhans cell migration) for the tested dosage will be compared to those obtained using the current dose herein of 20mg/ml. It is to be expected that an appropriate concentration of an IL-1 receptor antagonist in a vehicle for local administration to a human patient will be in the range of 20ng/ml to 20 mg/ml .
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP52393498A JP2002514194A (en) | 1996-11-19 | 1997-11-19 | Topical use of IL-1RA in rejection of corneal transplantation or eye disease |
EP97948458A EP0944395A1 (en) | 1996-11-19 | 1997-11-19 | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
AU54527/98A AU5452798A (en) | 1996-11-19 | 1997-11-19 | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
CA002272073A CA2272073A1 (en) | 1996-11-19 | 1997-11-19 | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75207596A | 1996-11-19 | 1996-11-19 | |
US7718696P | 1996-11-19 | 1996-11-19 | |
US60/077,186 | 1996-11-19 | ||
US08/752,075 | 1996-11-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998022130A1 true WO1998022130A1 (en) | 1998-05-28 |
WO1998022130A9 WO1998022130A9 (en) | 1998-08-27 |
Family
ID=26759000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/021393 WO1998022130A1 (en) | 1996-11-19 | 1997-11-19 | Local use of il-1ra in corneal transplant rejection or disorders of the eye |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0944395A1 (en) |
JP (1) | JP2002514194A (en) |
CA (1) | CA2272073A1 (en) |
WO (1) | WO1998022130A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999030730A1 (en) * | 1997-12-15 | 1999-06-24 | Universite Laval | Methods and compositions for improving the success of cell transplantation in a host |
JP2002520355A (en) * | 1998-07-14 | 2002-07-09 | アルコン ラボラトリーズ, インコーポレイテッド | 11- (3-Dimethylaminopropylidene) -6,11-dihydrodibenz [b, e] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ocular inflammatory disorders and preventing ocular neovascularization Use of |
EP1252895A1 (en) * | 2000-01-31 | 2002-10-30 | Santen Pharmaceutical Co., Ltd. | Remedies for ophthalmic diseases |
US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
US6733753B2 (en) | 1997-02-10 | 2004-05-11 | Amgen Inc. | Composition and method for treating inflammatory diseases |
EP2021026A1 (en) * | 2006-04-14 | 2009-02-11 | Novartis AG | Use of il-i antibodies for treating ophthalmic disorders |
WO2009025763A3 (en) * | 2007-08-16 | 2009-04-23 | Schepens Eye Res Inst | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
WO2010081091A3 (en) * | 2009-01-09 | 2010-11-18 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
US8911768B2 (en) | 2004-04-30 | 2014-12-16 | Allergan, Inc. | Methods for treating retinopathy with extended therapeutic effect |
US9012437B2 (en) | 2000-07-05 | 2015-04-21 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
US9192511B2 (en) | 2003-01-09 | 2015-11-24 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US9309313B2 (en) | 2008-01-09 | 2016-04-12 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
US10799589B2 (en) | 2013-03-13 | 2020-10-13 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009323A1 (en) * | 1994-09-21 | 1996-03-28 | Dompe' S.P.A | Il-1 receptor antagonists with enhanced inhibitory activity |
-
1997
- 1997-11-19 WO PCT/US1997/021393 patent/WO1998022130A1/en not_active Application Discontinuation
- 1997-11-19 CA CA002272073A patent/CA2272073A1/en not_active Abandoned
- 1997-11-19 EP EP97948458A patent/EP0944395A1/en not_active Withdrawn
- 1997-11-19 JP JP52393498A patent/JP2002514194A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996009323A1 (en) * | 1994-09-21 | 1996-03-28 | Dompe' S.P.A | Il-1 receptor antagonists with enhanced inhibitory activity |
Non-Patent Citations (7)
Title |
---|
DANA M R ET AL: "Topical interleukin - 1 receptor antagonist ( IL - 1ra ) suppresses Langerhans cell activity and promotes immune privilege.", ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, PARTS 1-2, FORT LAUDERDALE, FLORIDA, USA, MAY 11-16, 1997. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38 (4 PART 1-2). 1997. S705, XP002059495 * |
DANA M R ET AL: "Topical interleukin 1 receptor antagonist promotes corneal transplant survival.", TRANSPLANTATION (BALTIMORE) 63 (10). 1997. 1501-1507, XP002059498 * |
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; TORRES P F ET AL: "Cytokine mRNA expression during experimental corneal allograft rejection.", XP002059499 * |
EXPERIMENTAL EYE RESEARCH 63 (4). 1996. 453-461 * |
KENNEDY M C ET AL: "Novel production of interleukin - 1 receptor antagonist peptides in normal human cornea.", JOURNAL OF CLINICAL INVESTIGATION 95 (1). 1995. 82-88, XP002059496 * |
ROSENBAUM, JAMES T. ET AL: "Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis", ARCH. OPHTHALMOL. (CHICAGO) (1992), 110(4), 547-9, XP002059494 * |
TORRES P ET AL: "Interleukin 1-beta and interleukin 1 receptor antagonist expression during experimental corneal graft rejection.", ANNUAL MEETING OF THE INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, FORT LAUDERDALE, FLORIDA, USA, MAY 14-19, 1995. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 36 (4). 1995. S1009, XP002059497 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6733753B2 (en) | 1997-02-10 | 2004-05-11 | Amgen Inc. | Composition and method for treating inflammatory diseases |
WO1999030730A1 (en) * | 1997-12-15 | 1999-06-24 | Universite Laval | Methods and compositions for improving the success of cell transplantation in a host |
JP2002520355A (en) * | 1998-07-14 | 2002-07-09 | アルコン ラボラトリーズ, インコーポレイテッド | 11- (3-Dimethylaminopropylidene) -6,11-dihydrodibenz [b, e] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ocular inflammatory disorders and preventing ocular neovascularization Use of |
EP1252895A1 (en) * | 2000-01-31 | 2002-10-30 | Santen Pharmaceutical Co., Ltd. | Remedies for ophthalmic diseases |
EP1252895A4 (en) * | 2000-01-31 | 2003-04-16 | Santen Pharmaceutical Co Ltd | Remedies for ophthalmic diseases |
US9775849B2 (en) | 2000-07-05 | 2017-10-03 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
US9012437B2 (en) | 2000-07-05 | 2015-04-21 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
US10206934B2 (en) | 2000-07-05 | 2019-02-19 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
US9592242B2 (en) | 2000-11-29 | 2017-03-14 | Allergan, Inc. | Methods for treating edema in the eye and intraocular implants for use therefor |
US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
US7033605B2 (en) | 2000-11-29 | 2006-04-25 | Allergan, Inc. | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
US9283178B2 (en) | 2000-11-29 | 2016-03-15 | Allergan, Inc. | Methods for treating edema in the eye and intraocular implants for use therefor |
US10702539B2 (en) | 2003-01-09 | 2020-07-07 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US10076526B2 (en) | 2003-01-09 | 2018-09-18 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US9192511B2 (en) | 2003-01-09 | 2015-11-24 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US8911768B2 (en) | 2004-04-30 | 2014-12-16 | Allergan, Inc. | Methods for treating retinopathy with extended therapeutic effect |
US9233071B2 (en) | 2004-04-30 | 2016-01-12 | Allergan, Inc. | Methods for treating retinopathy with extended therapeutic effect |
EP2377553A1 (en) * | 2006-04-14 | 2011-10-19 | Novartis AG | Use of IL-1 antibodies for treating ophthalmic disorders |
EP2021026A1 (en) * | 2006-04-14 | 2009-02-11 | Novartis AG | Use of il-i antibodies for treating ophthalmic disorders |
US10105441B2 (en) | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
WO2009025763A3 (en) * | 2007-08-16 | 2009-04-23 | Schepens Eye Res Inst | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
US11241497B2 (en) | 2008-01-09 | 2022-02-08 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
US9872901B2 (en) | 2008-01-09 | 2018-01-23 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
US9309313B2 (en) | 2008-01-09 | 2016-04-12 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
EP2242504A4 (en) * | 2008-01-09 | 2017-05-03 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of ocular inflammatory disorders |
WO2010081091A3 (en) * | 2009-01-09 | 2010-11-18 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
US10117906B2 (en) | 2009-01-09 | 2018-11-06 | The Schepens Eye Research Institute, Inc. | Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra |
US9180090B2 (en) | 2009-07-03 | 2015-11-10 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US9161902B2 (en) | 2009-07-03 | 2015-10-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US9119771B2 (en) | 2009-07-03 | 2015-09-01 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8314083B2 (en) | 2009-07-03 | 2012-11-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US9458216B2 (en) | 2010-07-29 | 2016-10-04 | Eleven Biotherapeutics, Inc. | Nucleic acid encoding chimeric IL-1 receptor type I antagonists |
US8853150B2 (en) | 2010-07-29 | 2014-10-07 | Eleven Biotherapeutics, Inc. | Chimeric IL-1 receptor type I antagonists |
US10799589B2 (en) | 2013-03-13 | 2020-10-13 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
Also Published As
Publication number | Publication date |
---|---|
JP2002514194A (en) | 2002-05-14 |
CA2272073A1 (en) | 1998-05-28 |
EP0944395A1 (en) | 1999-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dana et al. | Topical interleukin 1 receptor antagonist promotes corneal transplant survival1 | |
Chang et al. | The role of the immune system in conjunctival wound healing after glaucoma surgery | |
WO1998022130A1 (en) | Local use of il-1ra in corneal transplant rejection or disorders of the eye | |
US5767079A (en) | Method of treating ophthalmic disorders using TGF -β | |
WO1998022130A9 (en) | Local use of il-1ra in corneal transplant rejection or disorders of the eye | |
RU2668371C2 (en) | Method for treating atrophic age related macular degeneration | |
US20030175849A1 (en) | Eye treatments using synthetic thyroid hormone compositions | |
JP2014014694A (en) | Sustained-release intraocular implant comprising vasodilator agent | |
KR20050057175A (en) | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders | |
WO1994001124A1 (en) | METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF-$g(b) | |
Dana | Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis) | |
Qian et al. | Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants | |
EP1223981B1 (en) | Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye | |
EP4311575A2 (en) | Methotrexate for proliferative vitreoretinopathy | |
WO1996009838A1 (en) | METHOD OF TREATING MACULAR DEGENERATION USING TGF-$g(b) | |
WO2000027421A2 (en) | LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE | |
Fei et al. | Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty | |
Koevary | Ocular immune privilege: a review | |
Wang et al. | Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4 (+) CD25 (+) Foxp3 (+) regulatory T cells | |
JPH08503968A (en) | Composition containing growth factor and antimetabolite | |
Wallentin et al. | Steroid and anti-CD18 treatment have no effect on after-cataract formation following surgery in rabbits | |
WO2000044396A1 (en) | Use of nerve growth factor for therapy of intraocular tissue pathologies | |
Doroodgar et al. | Main issues to overcome in modern penetrating keratoplasty | |
Doroodgar et al. | and Mohammad Ali Javadi | |
Ibrahim et al. | Ozurdex Intravitreal Injection Induced-Ptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ IL JP KR MX NO SG US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 21/98 UNDER (30) REPLACE "NOT FURNISHED 04.11.97 US" BY "60/077186 19.11.96 US" |
|
ENP | Entry into the national phase |
Ref document number: 2272073 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/004591 Country of ref document: MX Ref document number: 1997948458 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09308439 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997948458 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997948458 Country of ref document: EP |